Bladder Cancer
Early disease detection and diagnosis is paramount to improving health outcomes for bladder cancer patients. The detection of bladder cancer with DNA Fluorescence in situ Hybridization (FISH) probe technology equips pathologists with an insightful tool that detects molecular changes that may occur prior to morphological changes visible through traditional diagnostic procedures.
The UroVysion Bladder Cancer Kit is the first and only urine-based molecular diagnostic assay that aids in the initial diagnosis of bladder cancer while also detecting disease recurrence through subsequent monitoring. The UroVysion Bladder Cancer Kit is supported by years of scientific data allowing urologists to make evidence based decisions regarding therapeutic options for bladder cancer patients.
Understanding the need of laboratories and pathologists to produce and report consistent quality results with UroVysion, Abbott Molecular also provides the following accessory products:
- UroVysion Proficiency Panel
- ProbeChek Control Slide for UroVysion Bladder Cancer Kit
All Abbott Molecular probe kits are built with trusted Vysis probes providing
- Specific high-intensity signals without amplification and detection steps
- Low background for easy analysis
- Rapid, convenient, and easy-to-use assays
- Gene amplification detection including internal control probes
- Protocols that offer hybridization as quickly as four hours on the HYBrite and ThermoBrite Denaturation and Hybridization Systems
- Over 10 years of reliable results for researchers and clinicians worldwide
